Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 36 articles: HTML format

Single Articles

February 2026
1. MIRKHESHTI N, Kpormegbey DE, Weinstock C, Gao X, et al
   FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.
   Clin Cancer Res. 2026 Feb 12. doi: 10.1158/1078-0432.CCR-25-3609.
   PubMed     Abstract available
   
   
   
2. KATIMS AB, White C, Alam SM, Farha M, et al
   Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
   Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3395.
   PubMed     Abstract available
   
   
   
3. GUERCIO BJ, Pietzak EJ, Ravichandran V, Chen JF, et al
   Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
   Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-3771.
   PubMed     Abstract available
   
   
   January 2026
4. EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
   ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
   Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
   PubMed     Abstract available
   
   
   
5. CHEVRIER S, Richard C, Adotevi O, Ayyoub M, et al
   Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.
   Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-2306.
   PubMed     Abstract available
   
   
   October 2025
6. HEISS BL, Chang E, Joeng HK, Fiero MH, et al
   FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.
   Clin Cancer Res. 2025;31:4223-4229.
   PubMed     Abstract available
   
   
   
7. LIU Z, Zhang L, Jin K, Zeng H, et al
   ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.
   Clin Cancer Res. 2025;31:4311-4322.
   PubMed     Abstract available
   
   
   September 2025
8. STOCKEM CF, Gil-Jimenez A, Ali H, van Dorp J, et al
   Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
   Clin Cancer Res. 2025;31:3897-3906.
   PubMed     Abstract available
   
   
   July 2025
9. DE JONG JJ, Reike MJ, Lotan Y, Seiler R, et al
   Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy.
   Clin Cancer Res. 2025 Jul 15. doi: 10.1158/1078-0432.CCR-24-3726.
   PubMed     Abstract available
   
   
   June 2025
10. TATEO V, de Jong JJ, Cigliola A, Maiorano BA, et al
    Impact of molecular androgen and estrogen response scores on outcomes following neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    Clin Cancer Res. 2025 Jun 20. doi: 10.1158/1078-0432.CCR-24-4312.
    PubMed     Abstract available
    
    
    May 2025
11. RODRIGUEZ-MORENO JF, de Velasco G, Alvarez-Fernandez C, Collado R, et al
    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
    Clin Cancer Res. 2025;31:1644-1656.
    PubMed     Abstract available
    
    
    February 2025
12. GARCIA-DEL-MURO X, P Valderrama B, Medina-Colmenero A, Etxaniz O, et al
    Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
    Clin Cancer Res. 2025;31:659-666.
    PubMed     Abstract available
    
    
    January 2025
13. QIE Y, Huang S, Shen C, Wu Z, et al
    Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer.
    Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321.
    PubMed     Abstract available
    
    
    December 2024
14. COLBERT L, Jia Y, Sharma A, Hu J, et al
    FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Clin Cancer Res. 2024 Dec 20. doi: 10.1158/1078-0432.CCR-24-2812.
    PubMed     Abstract available
    
    
    
15. FLECHON A, Morales-Barrera R, Powles T, Alva A, et al
    Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:5353-5364.
    PubMed     Abstract available
    
    
    November 2024
16. BRAVE MH, Maguire WF, Weinstock C, Zhang H, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:4815-4821.
    PubMed     Abstract available
    
    
    September 2024
17. EISNER JR, de Jong FC, Shibata Y, Mayhew GM, et al
    Characterization of Fibroblast Growth Factor Receptor Alterations and Activation in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2024 Sep 26. doi: 10.1158/1078-0432.CCR-24-2015.
    PubMed     Abstract available
    
    
    
18. ZANG J, Shahatiaili A, Cai MC, Jin D, et al
    Genomic profiling and immune phenotyping of neuroendocrine bladder cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1277.
    PubMed     Abstract available
    
    
    July 2024
19. CHELUSHKIN MA, van Dorp J, van Wilpe S, Seignette IM, et al
    Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment.
    Clin Cancer Res. 2024 Jul 24. doi: 10.1158/1078-0432.CCR-24-0724.
    PubMed     Abstract available
    
    
    May 2024
20. MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:2011-2016.
    PubMed     Abstract available
    
    
    
21. BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Clin Cancer Res. 2024;30:2181-2192.
    PubMed     Abstract available
    
    
    January 2024
22. PETRYLAK DP, Eigl BJ, George S, Heath EI, et al
    Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:63-73.
    PubMed     Abstract available
    
    
    December 2023
23. LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
    Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Clin Cancer Res. 2023;29:4797-4807.
    PubMed     Abstract available
    
    
    November 2023
24. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    PubMed     Abstract available
    
    
    
25. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    PubMed     Abstract available
    
    
    
26. DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
    Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Clin Cancer Res. 2023;29:4373-4384.
    PubMed     Abstract available
    
    
    October 2023
27. KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
    Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
    PubMed     Abstract available
    
    
    
28. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    PubMed     Abstract available
    
    
    
29. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    PubMed     Abstract available
    
    
    September 2023
30. SALARI K, Sundi D, Lee JJ, Wu S, et al
    Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Clin Cancer Res. 2023;29:3668-3680.
    PubMed     Abstract available
    
    
    
31. JIANG D, Lan X, Cai W
    PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Clin Cancer Res. 2023;29:3259-3261.
    PubMed     Abstract available
    
    
    
32. DUAN X, Xia L, Zhang Z, Ren Y, et al
    First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2023;29:3395-3407.
    PubMed     Abstract available
    
    
    August 2023
33. ZHANG R, Zang J, Jin D, Xie F, et al
    Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
    PubMed     Abstract available
    
    
    June 2023
34. JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2023;29:2052-2065.
    PubMed     Abstract available
    
    
    April 2023
35. AGGEN DH, Chu CE, Rosenberg JE
    Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1377-1380.
    PubMed     Abstract available
    
    
    
36. KLUMPER N, Ralser DJ, Ellinger J, Roghmann F, et al
    Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1496-1505.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum